Axsome Therapeutics Gear Up for Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical company revolutionizing the treatment landscape for central nervous system (CNS) disorders, has exciting news for investors. The company is set to participate in a series of important investor conferences in May, where they will showcase their innovative approaches and advancements in neurology.
Key Conferences Where Axsome Will Present
In a display of transparency and commitment to its stakeholders, Axsome has confirmed its participation in four major investor conferences this coming May:
The Citizens 2025 Life Sciences Conference
Axsome will present on May 7, 2025, at 1:30 p.m. ET. This conference is a focal point for discussions surrounding innovations in life sciences and offers Axsome a platform to share insights about their ongoing projects and future perspectives.
BofA Securities 2025 Health Care Conference
On May 13, 2025, at 3:00 p.m. PT, Axsome will engage with a wide array of investors at BofA's Health Care Conference, showcasing their advancements and commitments to enhancing patient care in the CNS space.
RBC Capital Markets Global Healthcare Conference
Following that, on May 20, 2025, at 3:05 p.m. ET, Axsome will present at the RBC Capital Markets' Global Healthcare Conference, further highlighting their breakthroughs in CNS therapies.
Mizuho Neuro & Ophthalmology Summit 2025
Furthermore, Axsome will participate in investor meetings on May 21, 2025, at the Mizuho Neuro & Ophthalmology Summit, a significant event focusing on neuroscience and vision-related health innovations.
Access to Presentations and Webcasts
For investors who wish to follow along with these exciting presentations, live webcasts will be available for the sessions at the Citizens, BofA, and RBC conferences. These can be found on the Company’s official website in the “Webcasts & Presentations” section under “Investors.” Recordings of the presentations will be accessible for around 30 days after each conference, allowing investors to absorb all the critical information shared during these key events.
About Axsome Therapeutics
Axsome Therapeutics stands at the forefront of biopharmaceutical innovation, addressing significant gaps in CNS care. The company's mission centers around delivering groundbreaking scientific advancements that translate into meaningful improvements for patients suffering from various CNS disorders. Their impressive portfolio includes FDA-approved treatments for major depressive disorder, narcolepsy, and migraine, alongside multiple late-stage development programs targeting an extensive range of serious neurological and psychiatric conditions affecting over 150 million people across the United States.
With a strong focus on developing differentiated products that possess novel mechanisms of action, Axsome is dedicated to improving patient outcomes and enhancing quality of life. Their commitment not only reflects in their product offerings but also in their patient-centered approach, aiming to tackle some of the toughest challenges within the realm of brain health.
Investor and Media Contacts
For any inquiries, investors can reach Mark Jacobson, Chief Operating Officer, at (212) 332-3243 or via email at mjacobson@axsome.com. Media inquiries can be directed to Darren Opland, Director of Corporate Communications, at (929) 837-1065 or through email at dopland@axsome.com.
Frequently Asked Questions
What is Axsome Therapeutics known for?
Axsome Therapeutics is focused on developing innovative treatments for central nervous system disorders, improving patient care and outcomes.
When are the investor conferences scheduled?
Axsome will participate in four investor conferences throughout May, with key presentations on May 7, 13, 20, and 21, 2025.
How can investors access the presentations?
Investors can access live webcasts of the presentations via the “Webcasts & Presentations” page on the Company’s website, with replays available afterward.
What treatments does Axsome currently offer?
The company offers FDA-approved treatments for major depressive disorder, narcolepsy-related excess daytime sleepiness, migraine, and more.
How can I contact Axsome for more information?
Contact Mark Jacobson for investor queries and Darren Opland for media inquiries via the emails provided in the article.
